Aerpio Therapeutics Garners $27,000,000 Series A Funding Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c531f160-55a7-4c4b-8180-d12d692b4e71&Preview=1 -
Date
9/1/2012 -
Company Name
Aerpio Therapeutics -
Mailing Address
9987 Carver Road Cincinnati, OH 45242 -
Company Description
Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. -
Website
http://www.aerpio.com -
Transaction Type
Venture Equity -
Transaction Amount
$27,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The proceeds will support ongoing development of Aerpio’s pipeline, including AKB-9778, which is entering Phase 1b/2a for the treatment of diabetic macular edema (DME). -
M&A Terms
-
Venture Investor
Novartis BioVenture Fund -
Venture Investor
Venture Investors -
Venture Investor
Triathlon Medical Ventures -
Venture Investor
Kearny Venture Partners -
Venture Investor
Athenian Venture Partners -
Venture Investor
AgeChem Venture Fund
